^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Soltamox (tamoxifen citrate)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jazz
Drug class:
Estrogen receptor modulator
Related drugs:
22d
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)
P2/3, N=260, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion
|
BRAF (B-raf proto-oncogene)
|
Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)
5ms
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer (clinicaltrials.gov)
P2, N=19, Suspended, Stanford University | Active, not recruiting --> Suspended
Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
7ms
TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov)
P3, N=309, Recruiting, University of California, San Francisco | N=144 --> 309 | Trial completion date: Jan 2025 --> Mar 2026 | Trial primary completion date: Jan 2025 --> Mar 2026
Enrollment change • Trial completion date • Trial primary completion date
|
letrozole • Soltamox (tamoxifen citrate)
7ms
PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
P2, N=37, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
PGR positive
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
8ms
SOFT: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (clinicaltrials.gov)
P3, N=3066, Completed, ETOP IBCSG Partners Foundation | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: May 2014 --> Nov 2024
Trial completion • Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive
|
exemestane • triptorelin • Soltamox (tamoxifen citrate)
9ms
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Feb 2026
Trial completion date
|
ER (Estrogen receptor) • NCOA3 (Nuclear Receptor Coactivator 3)
|
ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
10ms
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
P2, N=74, Not yet recruiting, University of Chicago | Initiation date: Jan 2025 --> Jan 2026
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
10ms
EMPRESS: Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (clinicaltrials.gov)
P2, N=92, Completed, MedSIR | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
giredestrant (RG6171) • Soltamox (tamoxifen citrate)
11ms
MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
P1, N=15, Recruiting, University of Nebraska | Not yet recruiting --> Recruiting
Enrollment open
|
Soltamox (tamoxifen citrate)
11ms
EMPRESS: Preoperative Window Opportunity Study with Giredestrant or Tamoxifen in Premenopausal Women with ER+/HER2[-] & Ki67≥10% (clinicaltrials.gov)
P2, N=92, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Feb 2025
Enrollment closed • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
giredestrant (RG6171) • Soltamox (tamoxifen citrate)
11ms
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer (clinicaltrials.gov)
P=N/A, N=31, Terminated, Albert Einstein College of Medicine | N=132 --> 31 | Active, not recruiting --> Terminated; Interventional component of study terminated prior to full enrollment
Enrollment change • Trial termination
|
HER-2 (Human epidermal growth factor receptor 2)
|
paclitaxel • doxorubicin hydrochloride • cyclophosphamide • letrozole • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • Soltamox (tamoxifen citrate)
12ms
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov)
P2, N=100, Completed, Northwestern University | Recruiting --> Completed | Phase classification: P2b --> P2
Trial completion • Phase classification
|
ER (Estrogen receptor)
|
ER positive
|
afimoxifene • Soltamox (tamoxifen citrate)
Share via
